- Home
- ICCC
ICCC
ImmuCell Corporation
as of 12-18-2025 2:33pm EST
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | PORTLAND |
| Market Cap: | 55.5M | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 15.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.28 - $7.60 | Next Earning Date: | 11-13-2025 |
| Revenue: | $27,769,304 | Revenue Growth: | 16.49% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ICCC Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ImmuCell Corporation (ICCC)
President and CEO
Avg Cost/Share
$5.02
Shares
6,077
Total Value
$30,535.62
Owned After
6,264
President and CEO
Avg Cost/Share
$4.87
Shares
3,708
Total Value
$18,052.77
Owned After
6,264
SEC Form 4
Director
Avg Cost/Share
$4.76
Shares
3,266
Total Value
$15,554.33
Owned After
52,720
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| te Boekhorst Paul Francis Olivier | ICCC | President and CEO | Dec 3, 2025 | Buy | $5.02 | 6,077 | $30,535.62 | 6,264 | |
| te Boekhorst Paul Francis Olivier | ICCC | President and CEO | Dec 2, 2025 | Buy | $4.87 | 3,708 | $18,052.77 | 6,264 | |
| Tomsche David Scott | ICCC | Director | Nov 25, 2025 | Buy | $4.76 | 3,266 | $15,554.33 | 52,720 |
Compare ICCC vs Leading Stocks
See how ICCC stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ICCC ImmuCell Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.